

## REMARKS

### Status of the Claims

Claims 1-2, 5-12, 15, 17-25 and 28 are pending. Claims 1-2, 5-12, 15, 17-25 and 28 are rejected. Claims 1, 6-7, 15 and 28 are amended herein. Claims 2, 5 and 17-18 are canceled.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendments. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE". No new matter has been added. Reconsideration of the pending claims is respectfully requested.

### Amendments to the claims

Independent claims 1 and 15 are amended to overcome prior art rejections under 35 U.S.C. 102(b) & 102(e) and 103(a) as discussed *infra*. Additionally, Applicant has amended the preamble of claims 1 and 15 to recite transducing the conformational change of the ligand upon binding the signaling aptamer to a detectable increase in fluorescence intensity or colorimetric intensity and deleted this limitation from the body of the claims. Claim 2 was canceled to overcome the 35 U.S.C. 112, second paragraph

rejection. Claims 6-7 were amended to correct dependency. No new matter has been added.

The 35 U.S.C. §112, second paragraph rejections

Claim 2 is rejected under 35 U.S.C. §112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention in that the recitation "further comprises an electrochemical signal or an enzyme signal" lacks antecedent basis. Applicants respectfully traverse this rejection. Applicant has canceled claim 2 thereby rendering the rejection moot. Accordingly, Applicant respectfully requests that the rejection of claim 2 under 35 U.S.C. § 112, second paragraph, be withdrawn.

The 35 U.S.C. §102(b) & (e) rejections

Claims 1-2, 5-12, 15, 17, 19, 23, and 25 are rejected under 35 U.S.C. §102(b) as being anticipated by **Pitner et al.** (U.S. 5,650,275). Claims 1-2 and 7-12 are rejected under 35 U.S.C. §102(b) as being anticipated by **Gold et al.** (U.S. 6,242,246). Applicant respectfully traverses these rejections.

Regarding **Pitner et al.** and **Gold et al.** as applied to claim 1 and **Pitner et al.** as applied to claim 15, the Examiner states

that these references disclose the claimed invention method of detecting a differential/fluorescence signal of a signaling aptamer (detectably labeled nucleic acid ligand/fluorescent labeled polynucleotide) upon binding a ligand (target molecule), the differential/fluorescence signal generated by a reporter molecule/fluorescent dye (spectroscopically detectably labeled nucleic acid ligand/fluorescent label) comprising the steps of contacting (mixing) the signaling aptamer (spectroscopically detectably labeled nucleic acid ligand/fluorescent label) with the ligand (target compound) wherein the former binds (complexes with) the latter and detecting the differential signal/fluorescence signal generated by the reporter molecule/fluorescent dye (spectroscopically detectably labeled nucleic acid ligand/fluorescent label measured before and after binding) where the differential/fluorescence signal is expressed as fluorescence intensity (Pitner: col. 5, ll. 22-24; col. 13-14; claim 1 and **Gold et al.**: Abstract, ll. 2-14, col. 15, ll. 49-53, col. 16, ll. 54-57).

Additionally, the recitation in the instant claims of "transducing the conformational change of a signaling aptamer that occurs upon binding the signaling aptamer binding a ligand to a detectable optical signal generated by a reporter

molecule/fluorescent dye that is appended to the signaling aptamer at a site that does not interfere with a ligand-binding site of the signaling aptamer prior to binding the ligand” is inherent in the claim 1 method of **Pitner et al.** and of **Gold et al.** It was known in the prior art (see Description of the Related Art in the instant application) that aptamers undergo an induced fit conformational change in the presence of their cognate ligands and thus an appended dye easily undergoes a ligand-dependent change in its local environment (**Pitner et al.**: col. 2, lines 55-59; col. 11-12, Ex. 5 and **Gold et al.**: col. 15, lines 49-52, col. 16, lines 54-56).

**Pitner et al.** teach a method of detecting a target compound in a sample by measuring the fluorescent polarization or fluorescent anisotropy of a fluorescently labeled receptor molecule and subsequently measuring these values when the receptor molecule is placed in solution with the target compound. The labels are attached to the receptor molecule by chemical coupling of suitable reactive derivatives of the label molecule to suitable linkers or tethers. Commercial examples of these are amino hexyl or amino propyl linkers (col. 4, ll. 22-26).

**Gold et al.** disclose a nucleic acid ligand biochip having a solid support to which one or more specific nucleic acid ligands is

attached in a spatially defined manner. The nucleic acid ligands are contacted by a target molecules and if the target is bound by the nucleic acid ligand or receptor a detectable change occurs which is a change in fluorescence or a change in a physical property, e.g., electrical conductivity or refractive index (see Abstract). **Gold et al.** further disclose that a fluorophore such as fluorescein or Texas Red may be attached to the ligand on the biochip and binding of the target can be determined by measuring a change in fluorescence intensity, fluorescence polarization, fluorescence anisotropy and fluorescence lifetime (col. 15, lines 42-65).

Applicant has amended claims 1 and 15 to incorporate the covalent coupling limitation recited in claim 5 and incorporated the same limitation recited in claim 17 into claim 15, respectively. Thus the claims recite a step of appending the reporter molecule/fluorescent dye to the aptamer via covalent coupling to form the signaling aptamer. Additionally, the limitations recited in claim 18, drawn to the reporter molecule/fluorescent dye being inserted between two nucleic acid residues or replacing a nucleic acid residue, are incorporated into claim 15 and these limitations added to claim 1. Claims 5 and 17-18 are canceled.

As stated by the Examiner, neither **Pitner et al.** nor **Gold et al.** teach where the reporter molecule/fluorescent dye is placed within the aptamer. Furthermore, with respect to **Gold et al.**, claim 1 is amended to recite a step of placing the signaling aptamer in solution such that it is neither immobilized nor linked to a support and that the signaling aptamer free in solution is contacted by the ligand. **Gold et al.** specifically teach immobilizing or linking their fluorescently labeled nucleic acid ligands (the instant signaling aptamers) to a solid support or biochip (col. 15, lines 42-46).

Regarding dependent claims 2, 5-12, 17, 19, 23, and 25, Applicants have canceled claims 2, 5 and 17. The remaining dependent claims are drawn to the types of molecules used for the aptamers, reporter molecules and dyes, specific types of signaling aptamers and a method of quantitation using the methods recited in independent claims 1 and/or 15. As these claims depend from amended independent claims 1 or 15, neither **Pitner et al.** nor **Gold et al.** can anticipate these claims because neither **Pitner et al.** nor **Gold et al.** anticipate amended independent claims 1 and 15.

For a valid §102 rejection, the prior art references must contain each element of the claimed invention. Absent teachings of (1) covalently coupling the reporter/fluorescent dye between two

nucleic acid residues or covalently coupling the reporter/fluorescent dye by replacing a nucleic residue to form the signaling aptamer and (2) placing the signaling aptamer in solution neither immobilized nor linked to a support, neither **Pitner et al.** nor **Gold et al.** anticipate Applicant's claimed invention. Therefore, as this reference is not valid prior art against the instant application under 35 U.S.C. §102 and in view of the preceding amendments and remarks, Applicant respectfully submits that the cited references do not anticipate claims 1-2, 5-12, 15, 17, 19, 23, and 25 under 35 U.S.C. §102. Accordingly, Applicants respectfully request that the rejection of claims 1-2, 5-12, 15, 17, 19, 23, and 25 under 35 U.S.C. §102(b) and §102(e) be withdrawn.

The 35 U.S.C. §103(b) rejections

Claims 18, 20-22, and 24 are rejected under 35 U.S.C. §103(a) as being unpatentable over **Pitner et al.** as applied to claims 1-2, 5-12, 15, 17, 19, 23, and 25 above, and further in view of **Gold et al**, **Conrad** (U.S. 5,728,525) and **Szostak et al.** (U.S. 5,631,146). Claim 28 is rejected under 35 U.S.C. §103(a) as being unpatentable over **Pitner et al.** as applied to claims 1-2, 5-12, 15,

17, 19, 23, and 25 above and further in view of **Royer**. Applicant respectfully traverses this rejection.

With regard to claim 18, the Examiner states that it would have been obvious and the skilled practitioner would have been motivated at the time the claimed invention was made to label the nucleic acid ligand of **Pitner et al.** by replacing a nucleic acid residue with a fluorescent dye as disclosed in **Conrad** (col. 12, ll. 46-53) by replacing the residue during chemical or enzymatic synthesis. **Pitner et al.** is as described *supra*. **Conrad** teaches nucleoside analogs which are **inherently** (Applicant's emphasis) fluorescent (Abstract) and are useful as monomers in synthesizing and labeling nucleotide sequences. These monomers can substitute for naturally occurring nucleosides in the synthesis of oligonucleotide probes which are useful in oligonucleotide amplification, detection, identification, and/or hybridization assays (Abstract; col. 6, lines 45-51).

Although claim 18, which depended from independent claim 15, is canceled, the limitations of the claim are incorporated into both claims 1 and 15 to overcome the novelty rejections discussed *supra*. In considering what is fairly taught in **Conrad**, one of skill in the art would be motivated to prepare and use the

inherently fluorescent nucleoside analogs to synthesize a fluorescent oligonucleotide to use as a probe. However, because these analogs are autofluorescent, no change in fluorescence is detected upon the probe binding to a complementary sequence; the appearance of fluorescence in a recovered product simply indicates that a sequence complementary to the fluorescent probe was present or synthesized or hybridized depending on the particular use for the probe.

Therefore, this would not be an effective method of transducing a conformational change to an increase in fluorescence. Furthermore, **Conrad** does not teach a fluorescent probe comprising a fluorescent dye. In fact, no motivation to do so is found in **Conrad** because the novel fluorescent nucleoside analogs are already inherently fluorescent. Applicant respectfully submits that obviousness can not be established by combining the teachings of the prior art absent some teaching, suggestion or motivation supporting the combination to do so. Thus, absent the suggestion or motivation in **Conrad** to covalently couple a fluorescent dye within an oligonucleotide (aptamer) one of ordinary skill in the art in combining **Conrad** with **Pitner et al.** would not have Applicant's invention.

**Gold et al.** is as previously described. **Szostak et al.** teach single-stranded DNA molecules which bind adenosine or an adenosine-5'-phosphate and methods for producing and isolating them. **Royer** teaches a method of quantitation of a macromolecule in solution by measuring the changes in fluorescence polarization upon the association of the macromolecule with an oligonucleotide labeled with a fluorophore covalently coupled to the oligonucleotide (Abstract; claim 1). This is essentially the method of **Pitner et al.**

Claims 20-22, 24 and 28 depend from amended independent claim 15. Claims 20-22 and 25 limit the aptamers and ligands used in the instant method. Claim 28 limits the method by adding an additional step of quantitating the ligand through the increase in fluorescence intensity or colorimetric intensity. To reiterate the incorporation of claim 18 into claims 1 and 15 confers novelty on the instant invention, as recited in these amended claims. Furthermore, claim 18 does not render the instant invention obvious by the combination of **Pitner et al.** with **Conrad**. As such, further combinations of **Pitner et al.** and **Conrad** with **Gold et al.** and **Szostak et al.**, claims 20-22 and 24, and with **Royer et al.** (claim 28) also do not render the instant invention obvious. Thus, the invention as a whole was not obvious to one of ordinary skill in the

art at the time the invention was made. Accordingly, Applicants respectfully request that the rejection of claims 18, 20-22, 24, and 28 under 35 U.S.C. §103(a) be withdrawn.

This is intended to be a complete response to the Final Office Action mailed November 26, 2002. If any issues remain, the Examiner is respectfully requested to telephone the undersigned attorney of record for immediate resolution. Applicants enclose a Petition for a Two-Month Extension of Time. Please debit the \$205 extension fee under 37 C.F.R. 1.17(a)(2) or any additional fees from Deposit Account No. 07-1185.

Respectfully submitted,

Date:\_\_\_\_\_

\_\_\_\_\_  
Benjamin Aaron Adler, Ph.D., J.D.  
Registration No. 35,423  
Counsel for Applicant

ADLER & ASSOCIATES  
8011 Candle Lane  
Houston, Texas 77071  
(713) 270-5391 (tel.)  
(713) 270-5361 (facs.)  
BADLER1@houston.rr.com

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Please amend claim 1 as follows:

1. (twice-amended) A method of transducing the conformational change of a signaling aptamer that occurs upon the signaling aptamer binding a ligand to a detectable increase in fluorescence intensity or in colorimetric intensity ~~different~~ signal generated by a reporter molecule that is appended to the signaling aptamer prior to binding the ligand comprising the steps of:

appending the reporter molecule to an aptamer via covalent coupling to form the signaling aptamer, wherein the reporter molecule replaces a nucleic acid residue in the aptamer or is inserted between two nucleic acid residues in the aptamer such that the placement does not interfere with the ligand-binding site of the aptamer;

placing the signaling aptamer in solution wherein the signaling aptamer is neither immobilized on a support nor linked to a support;

contacting the signaling aptamer free in solution with the ligand under conditions whereby the signaling aptamer binds the ligand; and

detecting the increase in fluorescence intensity or in colorimetric intensity ~~differential signal~~ generated by the reporter molecule transduced by the conformational change in the signaling aptamer upon binding the ligand ~~wherein the differential signal is an optical signal expressed as fluorescence intensity or colorimetric intensity.~~

Please amend claim 6 as follows:

6. ( amended) The method of claim 1 ~~5~~, wherein the covalent coupling of the reporter molecule to the aptamer occurs during chemical synthesis, during transcription or post-transcriptionally.

Please amend claim 7 as follows:

7. ( amended) The method of claim 1 ~~5~~, wherein the reporter molecule is a dye.

Please amend claim 15 as follows:

15. (twice-amended) A method of transducing the conformational change of a signaling aptamer, that occurs upon the signaling aptamer binding a ligand to a detectable ~~optical signal~~ increase in fluorescence intensity or in colorimetric intensity generated by a fluorescent dye that is appended to the signaling aptamer prior to binding the ligand comprising the steps:

appending the fluorescent dye to an aptamer via covalent coupling to form the signaling aptamer, wherein the fluorescent dye replaces a nucleic acid residue in the aptamer or is inserted between two nucleic acid residues in the aptamer such that the placement does not interfere with the ligand-binding site of the aptamer;

placing the signaling aptamer in solution wherein the signaling aptamer is neither immobilized on a support nor linked to a support;

contacting the signaling aptamer in solution with the ligand under conditions whereby the signaling aptamer binds the ligand; and

detecting the increase in fluorescence intensity or in colorimetric intensity ~~optical signal~~ generated by the fluorescent

dye transduced by the conformational change of in the signaling aptamer upon binding the ligand, ~~wherein the optical signal is expressed as fluorescence intensity or colorimetric intensity.~~

Please amend claim 28 as follows:

28. (twice-amended) The method of claim 15, wherein the ligand is quantitated by the step comprising:

correlating the increase in fluorescence intensity or in colorimetric intensity ~~optical signal~~ generated upon the signaling aptamer binding the ligand with the quantity of ligand bound to the signaling aptamer.

Please cancel claims 2, 5 and 17-18.